Clinical Trials Logo

Clinical Trial Summary

Warts are common epidermal growths caused by various strains of human papilloma virus (HPV). Viral warts are common with a prevalence rate of 7-12%. Human papilloma virus is small non enveloped viruses that contain a double-stranded DNA genome. There are more than 200 HPV genotypes are reported, however, the high-risk types, including HPV genotype-16 (HPV16), 18, 31, and 45, are the causes of 80% of cervical cancers.


Clinical Trial Description

Cutaneous warts are benign lesions caused by low risk-HPV. Of which the most prevalent genotypes are HPV1/2/3/4/10/27/57, and from these genotypes 1, 2, 4, 27, 57 cause common warts. Palmoplantar warts can be caused by genotypes 1 and 2. Condyloma acuminata (anogenital warts) are common sexually transmitted infections caused primarily by HPV-6 and HPV-11 (in 90% of cases) and occasionally by HPV-16 and HPV-18. About 90% of HPV infections are eliminated within two years due to an efficient immune response. In the form of correct activation of the elements of the innate immune response, such as macrophages, polymorphonuclear cells, natural killer (NK) cells, which release immunomodulatory molecules that help control the infection. In addition, HPV-infected keratinocytes may act as non-professional antigen-presenting cells to promote the clearance of infected cells through the secretion of antiviral and pro-inflammatory mediators. Interferon (IFN) belongs to a family of inducible cytokines which promote an"antiviral state" in infected cells and neighboring cells through the activation of interferon-stimulated genes (ISG). Three IFN types have been identified (type I, II and III), of which I and III are involved in the innate immune response. Type I IFNs include IFN-α, IFN-β, IFN-ɛ, IFN-κ and IFN-ω. Most type I IFNs are induced through the binding of viral products to pattern recognition receptors, leading to activation of interferon response factors to drive the synthesis of IFN molecules. After secretion, type I IFNs bind to its receptor, which induces the phosphorylation of signal transducer and activator of transcription 1 (STAT1) and STAT2, which then translocate to the nucleus to induce transcription of (ISGs). The antiviral effects of IFN-I are mediated by inducing several (ISGs) which impair viral replication through inhibition of protein translation and degradation of viral RNA. ISGs also activate the survival of innate and adaptive immune cells including dendritic cells, macrophages, NK cells and T cells. So, IFN-I helps to control the infections. During the viral infection process, cytokines trigger and deal with inflammation. However, excessive production of cytokines can cause a cytokine storm, and excessive host innate immune response can also damage the body. Therefore, the suppressor of cytokine signaling proteins with negative feedback regulation ability, prevents the excessive secretion of cytokines from harming the host cell. These intracellular protein family is constituted by suppressor of cytokine signaling proteins 1-7, Which are potent endogenous inhibitors of Janus kinase (JAK/ STAT) signal. The SOCS 3 is mainly involved in the negative feedback regulation of the tyrosine-protein kinase/ STAT signaling. The critical role of SOCS3 is manifested by its binding to both the JAK and the tyrosine kinase receptor, which further inhibits STAT3 phosphorylation. The JAK/STAT pathway transduces extracellular signals to the nucleus. Its activation stimulates cell proliferation, differentiation, migration, and immune challenge. The JAK/STAT signaling pathway plays an important role in viral infection. The SOCS family are induced by various viral infections, including human immunodeficiency virus-1, hepatitis B and C viruses, herpes simplex virus type 1, respiratory syncytial virus, Ebola virus, influenza A, and coxsackie virus. Influenza A virus inhibits type I IFN signaling through the induction of SOCS3 expression. Newcastle disease virus (NDV) infection activates the expression of SOCS3 at the mRNA and protein level, which is conducive to the virus replication. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05781841
Study type Observational
Source Sohag University
Contact Reham H Aboelhamed, Demonstrator
Phone 01067017868
Email reham.helal@med.sohag.edu.eg
Status Not yet recruiting
Phase
Start date April 15, 2023
Completion date December 30, 2023

See also
  Status Clinical Trial Phase
Completed NCT01757392 - Candin Safety & Efficacy Study for the Treatment of Warts Phase 2
Completed NCT00973856 - Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands N/A
Completed NCT02902822 - Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo N/A
Withdrawn NCT00546611 - The Purpose of This Study is to Determine Whether Topical Application of PEP005 is Safe for the Treatment of Common Wart(s) Phase 1
Completed NCT00117871 - Study With a Topical Gel to Treat Common Warts in Adults Phase 2
Completed NCT04278573 - Intralesional Vitamin D Injection for Treatment of Common Warts Phase 2
Completed NCT02231879 - Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome Phase 2/Phase 3
Completed NCT06309420 - Clinical Trial to Evaluate Efficacy and Safety of a Cryogenic Medical Device for Treatment of Common and Plantar Warts N/A
Not yet recruiting NCT05616078 - Laser Versus Cryotherapy for the Treatment of Recalcitrant Warts N/A
Not yet recruiting NCT05617950 - Salicylic Acid Versus Cryotherapy for the Treatment of HPV1-induced Plantar Warts N/A
Recruiting NCT01712295 - 17% Salicylate Versus 17% Salicylate-Ethyl Pyruvate for Plantar Foot Warts Phase 4
Active, not recruiting NCT00254280 - Treatment of Recalcitrant Hand and Foot Warts With Intense Pulsed Light - a Randomized Controlled Trial N/A
Completed NCT04781244 - Cost-effectiveness of EndWarts® FREEZE - an Alternative Home Cryotherapy Device for Wart Treatment N/A
Completed NCT01101750 - Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Phase 4
Completed NCT03487549 - Cantharidin and Occlusion in Verruca Epithelium Phase 2
Recruiting NCT05625633 - Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts Phase 2/Phase 3
Completed NCT02393417 - Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris) Phase 2
Completed NCT01808443 - Efficacy of Laser Versus Cryotherapy in the Treatment of Warts N/A
Completed NCT00116662 - An up to Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects Phase 2
Completed NCT00116675 - Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects Phase 2